Larson Financial Group’s Viridian Therapeutics VRDN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$148K Sell
7,183
-599
-8% -$12.8K ﹤0.01% 1072
2026
Q2
$143K Buy
7,782
+6,860
+744% +$111K ﹤0.01% 998
2026
Q1
$18K Buy
922
+9
+1% +$267 ﹤0.01% 1906
2025
Q4
$28.4K Sell
913
-1,494
-62% -$41K ﹤0.01% 1521
2025
Q3
$51.9K Buy
+2,407
New +$43.4K ﹤0.01% 1145
2025
Q2
– Sell
-8
Closed -$108 – 3510
2025
Q1
$108 Buy
+8
New +$136 ﹤0.01% 2900

Other funds holding VRDN

Larson Financial Group's VRDN Position: Q3 2026 in Review

Larson Financial Group reduced its Viridian Therapeutics (VRDN) stake by 7.7% in Q3 2026, selling an estimated $12.8K and leaving 7,183 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #1072.

Larson Financial Group first reported a position in VRDN in Q1 2025 and has held it in 6 quarters since. 235 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

  • Larson Financial Group held 7,183 shares of Viridian Therapeutics worth $148K as of Q3 2026.
  • Larson Financial Group sold 599 Viridian Therapeutics shares in Q3 2026, an estimated $12.8K.
  • Viridian Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q3 2026, its #1072 holding.
  • Larson Financial Group first reported a position in Viridian Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 235 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.